$JKHY

JACK HENRY & ASSOCIATES INC (JKHY): Results of Operations and Financial Condition

JACK HENRY & ASSOCIATES INC (JKHY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 jkhy-20260630xex99pressrel.htm EX-99.1 - JKHY - 2026.06.30 - Q4 FY26 PRESS RELEASE Document Press Release Mimi L. Carsley | Chief Financial Officer | mcarsley@jackhenry.com FOR IMMEDIATE RELEASE Jack Henry & Associates, Inc. Reports Fourth Quarter and Full Year Fiscal 2

Original reporting
Published Aug 18, 2026, 8:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$JKHY
Neutral
medium confidence
Mentioned
$JKHY
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JKHYNeutralMed
01

Why it matters

The filing is a direct earnings-and-guidance disclosure with numeric ranges for FY27 revenue, operating margin, and EPS, alongside capital return (repurchases) and balance-sheet updates.

02

Market read

Traders can update expectations immediately using the provided FY27 guidance ranges and the mix of GAAP versus non-GAAP performance in Q4 and FY26.

03

What to watch

Non-GAAP strength may be driven by adjustments; traders may focus on the specific drivers of GAAP operating income decline and the sustainability of faster payments and digital transaction growth.

Relevance 8/10Novelty 8/10Timing: after-hours filing on Aug 18, 2026 (FY26 results and FY27 guidance)

Background

The SEC 8-K includes Item 2.02 results and an attached press release (EX-99.1) covering fiscal Q4 and full-year ended June 30, 2026, plus FY27 guidance.

Company-level read

Ticker impact

$JKHYNeutralMedium confidence
Context

Jack Henry reported fiscal Q4 and full-year FY26 results plus fiscal 2027 guidance, including GAAP and non-GAAP revenue, EPS, and margins.

Expected impact

Near-term bias depends on how investors weigh Q4 GAAP operating income and EPS contraction versus record sales, non-GAAP strength, and FY27 guidance range.

Evidence & confidence

The filing provides concrete quarterly and full-year GAAP/non-GAAP figures and a numeric FY27 guidance range, which typically drives repricing around expectations and margin durability.

Market effects

Signals continued demand for financial technology spending by banks and credit unions, with emphasis on cloud hosting, faster payments, and AI-related solutions.

Primarily US-focused financial IT demand; limited direct regional spillover beyond US bank IT budgets.

Moderate, as the company’s customer base is largely US financial institutions, though faster payments and cloud trends are globally relevant.

Counterpoint

Investors may discount guidance if they view Q4 GAAP operating income and EPS contraction as a sign of cost pressure that could persist into FY27.

Key entities

  • Jack Henry & Associates, Inc.

    Financial technology provider reporting FY26 results and issuing FY27 GAAP and non-GAAP guidance.

  • Greg Adelson

    President and CEO quoted on record sales, competitive core wins, and AI expansion.

  • Mimi L. Carsley

    CFO listed in the press release for the FY26 results.

Related articles

$JKHYLow

JACK HENRY & ASSOCIATES INC (JKHY): Results of Operations and Financial Condition

JACK HENRY & ASSOCIATES INC (JKHY) filed an SEC Form 8-K — Results of Operations and Financial Condition. jkhy-20260811 0000779152 2026 FY FALSE 0000779152 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event re

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$CSANMed

Cosan Q2 Earnings Call Highlights

Cosan reported a debt service coverage ratio of 0.2x, down from the prior quarter, and expects it to reach 0.8x-1.2x by year-end. The company plans to delist its ADS from the NYSE and reduce overhead. Investees showed mixed performance, with Rumo's EBITDA stable, Compass up 5%, and Moove down 6% YoY. Cosan is pursuing divestments, including a stake in Terminal de Uso Privado Porto São Luís for BRL 300M.

$SLNGMed

Stabilis Solutions (SLNG) Q2 2026 Earnings Call Transcript

Stabilis Solutions (SLNG) reported Q2 2026 revenue of $11.9M, down 31% YoY due to completed contracts. The company expects second-half revenue to increase over 50% compared to the first half, driven by new data center and aerospace contracts. A large 2027 contract is expected to generate $100M annually. The Galveston LNG project faces delays but has received regulatory approvals. Adjusted EBITDA was $0.1M, excluding $2.9M in vessel charter costs.